JC13 Rec CT/PTO 01 APR 2005

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q87150

Hideki FUJIKURA, et al.

Appln. No.: NOT YET ASSIGNED (371 of PCT/JP2003/012477)

Confirmation No.: Not Yet Assigned Group Art Unit: NOT YET

ASSIGNED

Filed: April 01, 2005 Examiner: NOT YET ASSIGNED

For: PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING

THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATE

IN PRODUCING THE SAME

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003. The listed documents indicated are on the attached CD.

JC13 Rec CT/PTO 01 APR 2005

INFORMATION DISCLOSURE STATEMENT U.S. Appln. No.: NOT YET ASSIGNED (371 of PCT/JP2003/012477)

The present Information Disclosure Statement is being filed:

- (1) No later than three months from the application's filing date;
- (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

(UNUL

Peter D. Olexy

Respectfully submitted,

Registration No. 24,513

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: April 1, 2005

ete if Known Application Substitute for Form 1449 A & B/PTO Number NOT YET ASSIGNED Confirmation INFORMATION DISCLOSURE NOT YET ASSIGNED Number STATEMENT BY APPLICANT Filing Date April 01, 2005 First Named (use as many sheets as necessary) Hideki FUJIKURA Inventor NOT YET ASSIGNED Art Unit Examiner Name NOT YET ASSIGNED Attorney Docket 0 1 2 Sheet Q87150 Number

U.S. PATENT DOCUMENTS								
Evamina		Document Numb	er	Publication Date MM-DD-YYYY				
Examine r Initial s*	Cite No. ¹	Number	Kind Code ² (if known)		Name of Patentee or Applicant of Cited Documer			
		US 6,414,126	B1	07-02-2002	Ellsworth, et al.			
		US 6,515,117	B2	02-04-2003	Ellsworth, et al.			
		US 2002/0137903	A1	07-24-2003	Hiranuma, et al.			
		US 2004/053397	A1	03-18-2004	Iwamoto, et al.			
		US 2004/132669	A1	07-08-2004	Nishimura et al.			
		US 2004/116357	A1	06-17-2004	Fushimi et al.			
		US 2004/110936	A1	06-10-2004	Ohsumi et al.			
		US 2004/176308	A1	09-09-2004	Shiohara et al.			
		US 2003/0087843	A1	05-08-2003	Washburn			

FOREIGN PATENT DOCUMENTS									
Examine r Initial s*	Cite No.1	For	reign Patent Docu	ment	Publication Date MM-DD-YYYY				
		Count ry Code ³	Number ⁴	Kind Code ⁵ (if known)		Name of Patentee or Applicant of Cited Document	Translation 6		
		WO	01/16147	A1	03-08-2001	Kissei Pharmaceutical Co., Ltd.			
		WO	02/053573	A1	07-11-2002	Kissei Pharmaceutical Co., Ltd.			
		WO	02/053738	A1	07-11-2002	Kissei Pharmaceutical Co., Ltd.			
		wo	02/068439	A1	09-06-2002	Kissei Pharmaceutical Co., Ltd.			
		wo	02/068440	A1	09-06-2002	Kissei Pharmaceutical Co., Ltd.			
		WO	02/088157	A1	11-07-2002	Ajinomoto Co., Inc.			
		WO	02/098893	A1 .	12-12-2002	Kissei Pharmaceutical Co., Ltd.			
		WO	03/020737	A1	03-13-2003	Bristol Myers Squibb Co.			
		JP	2003-012686	А	01-15-2003	Kyowa Hakko Kogyo Co., Ltd.			

		NON PATENT LITERATURE DOCUMENTS	
Examine r Initial s*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation
		YAMANOUCHI, T. et al., Common reabsorption system of 1, 5-anhydro-D-glucitol, fructose, and mannose in rat renaltubule., Biochim. Biophys.Acta., 1996, 1291, pages 89 to 95	

Examiner		Date	
Signature	·	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.

10/529895

MODIFIED PTO/SB/08 A.& B (06-03)

·				JU13 Rec'd R	TO VIAPR ZUUS		
				Complete if Known			
Substitute for Form	1449 A & B/PTO			Application Number	NOT YET ASSIGNED		
	MATION DISC			Confirmation Number	NOT YET ASSIGNED		
STATE	MENT BY APP	PTC.	ANT	Filing Date	April 01, 2005		
(use as ma	ny sheets as	nec	essary)	First Named Inventor	Hideki FUJIKURA		
				Art Unit	NOT YET ASSIGNED		
				Examiner Name	NOT YET ASSIGNED		
Sheet	2		2	Attorney Docket Number	Q87150		

U.S. PATENT DOCUMENTS								
Examine r Initial s*	Cite No.1	Document 1	Number	Publication Date MM-DD-YYYY				
		Number	Kind Code ² (if known)		Name of Patentee or Applicant of Cited Documer			
		US						
		ŲS						
		US						
		ÚS						
		US						
		US						
		US						

				FOREIGN P	ATENT DOCUME	INTS	
Examine r Initial s*	Cite No.1	Foreign Patent Document			Publication		•
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)	Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translat ion ⁶
I		WO	01/27128	A1	04-19-2001	Bristol Myers Squibb Co.,	1
1 W - A		WO	02/36602	A1	05-10-2002	Ajinomoto Co., Inc.	
)	EP	1338603	A1	08-27-2003	Ajinomoto Co., Inc.	
		EP	1213296	A1	06-12-2002	Kissei Pharmaceutical Co., Ltd.	
		EP	1354888	A1	10-22-2003	Kissei Pharmaceutical Co., Ltd.	
			<u> </u>	<u> </u>		<u> </u>	

NON PATENT LITERATURE DOCUMENTS							
Examine r Initial s*	Cite No.¹	<pre>Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.</pre>	Translat ion ⁶				

Examiner	Date	
Signature	Considered	
	 	 •

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.